UBC Theses and Dissertations
Is iron deficiency a major cause of the high prevalence of anemia in non-pregnant Cambodian women of reproductive age? : evidence from a cross-sectional survey and a randomized controlled trial Karakochuk, Crystal D.
Despite a high prevalence of anemia among non-pregnant Cambodian women, recent reports suggest iron deficiency prevalence is low. If true, iron supplementation will not reduce anemia. In Phase I, we investigated factors associated with hemoglobin, ferritin, and soluble transferrin receptor (sTfR) concentrations in 450 women 18-45 years in Prey Veng province. Overall, 54% had a genetic hemoglobin disorder, 29.5% had anemia (hemoglobin <120 g/L), and 2% and 19% had iron deficiency based on ferritin (<15 µg/L) and sTfR (>8.3 mg/L), respectively. The hemoglobin E homozygous genotype was associated with 50% (95% CI: 14%, 96%) and 51% (95% CI: 37%, 66%) higher mean ferritin and sTfR concentrations as compared to normal hemoglobin structure. These findings challenged the diagnostic accuracy of ferritin and sTfR to estimate iron deficiency. In Phase II, we measured the effect of oral iron (Fe) with or without multiple micronutrients (MMN) on hemoglobin concentration as a direct way to determine the extent to which iron deficiency (or other micronutrient deficiencies) was a cause of anemia. A total of 809 non-pregnant women 18-45 years with hemoglobin ≤117 g/L (HemoCue®) were recruited from Kampong Chhnang province to a 2x2 factorial double-blind randomized trial. Women received 12 weeks of daily Fe (60 mg), MMN (14 other micronutrients), Fe+MMN, or placebo capsules. Baseline anemia prevalence was 58% (Sysmex analyzer). Mean (95% CI) hemoglobin at 12 weeks did not differ in the Fe and Fe+MMN groups (121 [120, 122] vs. 123 [122, 124] g/L); both were higher than MMN and placebo (both 116 [115, 117] g/L, P<0.05). Mean (95% CI) increase in hemoglobin was 5.6 (3.8, 7.4) g/L (P<0.001) among women who received Fe (n=383) and 1.1 (-0.7, 2.9) g/L (P=0.24) among women who received MMN (n=382), with no interaction between interventions (P=0.61). At 12 weeks, 19% and 30% of women had a hemoglobin response ≥10 g/L in Fe and Fe+MMN groups, compared to 8% and 5% in MMN and placebo, respectively. Daily iron supplementation for 12 weeks increased hemoglobin in non-pregnant Cambodian women; however, MMN did not confer additional benefit. Only ~25% of our predominantly anemic study population was responsive to iron.
Item Citations and Data
Attribution-NonCommercial-NoDerivatives 4.0 International